Insomnia Epidemiology

DelveInsight’s ‘Insomnia – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of Insomnia, historical and forecasted epidemiology, as well as the Insomnia trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Insomnia Disease Understanding

Insomnia is a common sleep–wake disorder characterized by nocturnal and diurnal symptoms. It involves a predominant complaint of dissatisfaction with sleep quality or duration. It is accompanied by difficulties initiating sleep at bedtime, frequent or prolonged awakenings, or early-morning awakening with an inability to return to sleep. According to the American Academy of Sleep Medicine, Insomnia is difficulty falling or staying asleep accompanied by daytime impairments related to those sleep troubles.

According to the International Classification of Sleep Disorders 3rd edition criteria, Insomnia disorder is defined as complaints of difficulty initiating sleep (DIS), and/or difficulty maintaining sleep (DMS), and/or early morning awakenings (EMA). These nocturnal symptoms must be accompanied by daytime impairment related to sleeping difficulties.

DSM-V defines insomnia as dissatisfaction with sleep quantity or quality, often associated with either difficulty initiating or maintaining sleep. It is characterized by frequent awakenings or problems returning to sleep after awakenings. This sleep difficulty is present for at least 3 months or occurs at least 3 nights per week. The condition has been renamed Insomnia disorder.

There is no single established cause of insomnia. However, research suggests that in many people, it results from certain physiological arousal at unwanted times, disrupting standard sleep patterns. Such arousal can include a heightened heart rate, a higher body temperature, and increased levels of specific hormones like cortisol. It also often occurs along with various mental disorders.

Insomnia was previously subdivided into many different types, including primary and secondary insomnia. Recently, these categories were changed American Academy of Sleep Medicine categorizes insomnia into short-term, chronic, and other insomnia. Other previously used subtypes now under chronic insomnia included paradoxical, idiopathic, psychophysiological, and inadequate sleep hygiene, among others. These subtypes were recently removed in the new ICSD-III.

Chronic Insomnia is when a person experiences sleeping difficulties and related daytime symptoms, like fatigue and attention issues, at least 3 days per week for more than 3 months or repeatedly over the years. Short-term insomnia r involves the same sleep difficulties and symptoms as chronic, but those problems are experienced for less than 3 months and may not occur three times per week. In specific cases, a doctor may diagnose a condition called other insomnia disorder if a person has significant sleeping problems but does not meet all of the criteria for either chronic or short-term insomnia disorder.

Increasing age, female gender, medical and psychiatric disease, and shift work all independently predict the risk of developing chronic insomnia. Insomnia is more prevalent in older populations. The elderly are prone to several risk factors, such as increased prescription drug use, somatic disorders, neurological decline, reduced exposure to outdoor light, and polyphasic sleep–wake patterns. Lack of physical activity also may play a role in the age-related increase in insomnia prevalence.

Insomnia Diagnosis

Diagnosis of insomnia is based on the subjective complaint of difficulties initiating or maintaining sleep and reports of substantial distress or daytime impairments. Currently, two modalities help objectively measure sleep activity: actigraphy and polysomnography. Actigraphy is a technique for measuring limb movement activity with wearable actigraphic devices on wrists or ankles. The data for movement activity is gathered over time, ultimately giving patterns for wakefulness and sleep. With the patterns, general sleep parameters can be obtained, including sleep latency, sleep efficiency, total sleep time, and wake after sleep onset. These parameters greatly aid in evaluating insomnia. Non-REM and REM sleep cycles cannot be gathered and need polysomnography to assess. Although polysomnography is the golden standard in measuring sleep-related disorders, it is not used routinely for diagnosing insomnia. In insomnia cases, it is usually indicated when there is suspicion that another sleep-related disorder is possible. Such conditions include breathing disorders such as obstructive sleep apnea, central sleep apnea, or sleep-related movement disorders.

Questionnaires such as the Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index (PSQI) are tools that aid in the diagnosis of insomnia. The Insomnia Severity Index consists of seven questions with a score of 1–4. The maximum score is 28; the higher the score, the worse insomnia. A score of greater than 14 indicates clinical insomnia. The questionnaire can be self-administered by patients and brought in for evaluation by the provider. The PSQI was developed to help differentiate between different sleep-related disorders. It consists of 19 questions and measures different domains of sleep (quality, latency, duration, efficacy, medication use, daytime symptoms, and disturbances) over a month.

Continued in the report…..         

Insomnia Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Insomnia, Type-specific Cases of Insomnia, Gender-specific Cases of Insomnia, and Age-specific Cases of Insomnia scenario of Insomnia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

Insomnia Detailed Epidemiology Segmentation

• In 2022, the total diagnosed prevalent cases of insomnia were estimated to be approximately 86,512,557 cases in the 7MM. These cases are expected to increase by 2034 at a CAGR of 0.6% during the study period (2021-2034).
• Among the 7MM, the United States accounted for nearly 67% of the total diagnosed prevalent cases of insomnia in the year 2022. These cases are expected to increase further during the study period (2021-2034).
• As per DelveInsight analysis, there were approximately 31,830,445 cases of acute insomnia in the US and 26,306,153 cases of chronic insomnia in 2022, which are expected to increase by 2034.
• According to estimates based on DelveInsight’s epidemiology model of Insomnia, the age-specific cases of insomnia in EU4 and the UK in 2022 were approximately 2,214,257, 3,728,920, 3,763,699, 3,981,128, 4,011,010, and 5,512,387 in the age groups 18-24, 25-34, 35-44, 45-54, 55-64, and 65+, respectively.
• In 2022, in Japan, there were approximately 2,247,099 cases of insomnia in males and 2,917,458 cases of insomnia in females. These gender-specific cases are expected to decrease in Japan by 2034.
• According to estimates based on DelveInsight’s epidemiology model of insomnia, in 2022, in EU4 and the UK, there were approximately 9,869,071 cases of acute insomnia and 13,342,330 cases of chronic insomnia, which are expected to increase by 2034.

Scope of the Report

• The report covers a descriptive overview of Insomnia, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of Insomnia.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report describes the disease epidemiology for the 7MM, Total Diagnosed Prevalent Cases of Insomnia, Type-specific Cases of Insomnia, Gender-specific Cases of Insomnia, and Age-specific Cases of Insomnia.

Report Highlights

• 10-Year Forecast of Insomnia
• The 7MM Coverage
• Total Diagnosed Prevalent Cases of Insomnia
• Type-specific Cases of Insomnia
• Gender-specific Cases of Insomnia
• Age-specific Cases of Insomnia

Key Questions Answered

• What are the disease risk and burdens of Insomnia?
• What is the historical Insomnia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of Insomnia at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population with Insomnia?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Insomnia during the forecast period (2025-2034)?
• At what CAGR is the population expected to grow across the 7MM during the forecast period (2025-2034)?

Reasons to buy

The Insomnia report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Insomnia epidemiology forecast.
• The Insomnia epidemiology report and model were written and developed by Master’s and PhD level epidemiologists.
• The Insomnia epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by the Segmentation
• actors Driving Growth in a Specific Patient Population